Long-acting injectable antipsychotics (LAIs) are crucial for maintaining treatment in individuals with schizophrenia (SCZ) or bipolar I disorder (BP-I), the use of which decreased early in the COVID-19 pandemic due to reduced face-to-face consultations.
